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The inward rectiﬁer family of potassium (Kir) channels is comprised of at least 16 family
members exhibiting broad and often overlapping cellular, tissue, or organ distributions.The
discovery of disease-causing mutations in humans and experiments on knockout mice
has underscored the importance of Kir channels in physiology and in some cases raised
questions about their potential as drug targets. However, the paucity of potent and selec-
tive small-moleculemodulators targeting speciﬁc family members haswith few exceptions
mired efforts to understand their physiology and assess their therapeutic potential. A grow-
ing body of evidence suggests that G protein-coupled inward rectiﬁer K (GIRK) channels
of the Kir3.X subfamily may represent novel targets for the treatment of atrial ﬁbrillation.
In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl+)
ﬂux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One
compound, termedVU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC50 = 1.9 and
19μM, respectively) and was therefore selected for further study. In electrophysiological
experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited
Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and
preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl+ ﬂux assays were
established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry
efforts to develop more potent and selective analogs for these channels. The structure–
activity relationships of VU573 revealed few analogs with improved potency, however two
compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward
Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and
structure–function relationships of these Kir channels.
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INTRODUCTION
The inward rectiﬁer family of potassium (Kir) channels is com-
prised of at least 16 family members exhibiting unique func-
tional and regulatory properties that enable them to carry out
important functions in most organ systems (Hebert et al., 2005;
Hibino et al., 2010). Kir channels preferentially pass current in
the inward direction at voltages more negative than the Nernst
electrochemical equilibrium potential for potassium (EK). Unlike
their voltage-gated potassium channel counterparts, Kir channels
lack discrete voltage-sensing domains that regulate pore opening.
Rather, the rectiﬁcation of the channel conductance-voltage rela-
tionship is due to voltage-dependent pore block by magnesium
and polyamines at potentials more positive than EK. The degree
of rectiﬁcation varies widely between family members and is used
to categorize them functionally into groups of strong versus weak
rectiﬁers. In general, strong rectiﬁers are expressed in excitable
cells such as neurons and muscle cells, whereas weak rectiﬁers are
expressed in epithelial and other non-excitable cell types (Hib-
ino et al., 2010). Some Kir channels are postulated therapeutic
targets for common diseases (Bhave et al., 2010). Consequently,
we have been working to develop small-molecule probes of clin-
ically relevant Kir channels to provide sharper pharmacological
tools with which to study their physiological roles and therapeutic
potential.
The founding Kir channel family member Kir1.1, is a weak rec-
tiﬁer encoded by the gene KCNJ1 (Ho et al., 1993; Zhou et al.,
1994). Kir1.1 is expressed almost exclusively in epithelial cells of
the renal tubule where it critically regulates salt and water balance
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and hence blood volume and pressure (Welling and Ho, 2009).
Autosomal recessive mutations in KCNJ1 give rise to antenatal
Bartter syndrome, a severe salt and water wasting disorder char-
acterized by hypokalemic metabolic alkalosis and low to normal
blood pressure (Simon et al., 1996). In contrast, heterozygous car-
riers of KCNJ1 mutations have lower blood pressure but no overt
evidence of disease (Ji et al., 2008). These genetic data raise the
intriguing possibility that Kir1.1 represents a drug target for a
novel class of diuretic. Consequently, our group recently employed
high-throughput screening and medicinal chemistry to develop
the ﬁrst publicly disclosed small-molecule inhibitors of Kir1.1
(Lewis et al., 2009; Bhave et al., 2011). These, as well as inhibitors
recently disclosed by investigators atMerck (Pasternak et al., 2010),
should be instrumental in assessing the therapeutic potential of
Kir1.1 for the management of hypertension.
Another emerging drug target in the Kir channel family is the
G protein-coupled inward rectiﬁer potassium (GIRK) channel,
which is expressed in the heart and throughout the nervous system
(Hibino et al., 2010). Themajor cardiac formof GIRK is a heterote-
trameric channel comprised of Kir3.1 and Kir3.4 subunits, which
is expressed primarily in atrial but not ventricularmyocytes. In the
nervous system, heteromeric GIRK channels are primarily formed
byKir3.1 andKir3.2. In the basal state,GIRKchannels exhibit a low
open-state probability and therefore contribute little to the rest-
ingmembrane potassium conductance and potential. In the heart,
sympathetic release of acetylcholine (ACh) onto M2 muscarinic
receptors leads toGprotein-dependent opening of GIRKchannels,
potassium efﬂux, and consequent membrane hyperpolarization.
The ACh-induced increase in potassium conductance slows the
rate of membrane depolarization, action potential generation, and
heart rate. In patients with chronic atrial ﬁbrillation, GIRK chan-
nels become constitutively active in atrial cardiomyocytes through
mechanisms that are incompletely understood (Dobrev et al.,
2005; Voigt et al., 2007; Makary et al., 2011). This background
current hyperpolarizes the membrane potential, abbreviates the
action potential, and increases the availability sodium channels for
activation. A growing body of experimental and clinical data sup-
port the notion that electrical remodeling sets up high-frequency
re-entrant current sources that perpetuate atrial ﬁbrillation, sug-
gesting that a speciﬁc blocker of GIRK could have anti-arrhythmic
actions without the ventricular side effects commonly associated
with current therapies (reviewed in Wakili et al., 2011). Similarly,
the other Kir channel family member Kir2.3 is enriched in atrial
cardiomyocytes and may also be a pharmaceutical target for atrial
ﬁbrillation (Ehrlich, 2008).
The molecular pharmacology of GIRK and most other inward
rectiﬁers is limited. A high-throughput screen using a voltage-
sensitive dye identiﬁed analogs of amiloride (a K+ sparing
diuretic) and propafenone (a class 1c anti-arrhythmic) that inhibit
GIRK with sub-micromolar potencies (Walsh, 2010). These and
several cardiac and neurological drugs exhibiting weak off-target
activity toward GIRK (reviewed in Bhave et al., 2010) may be
useful lead compounds for developing more speciﬁc inhibitors of
GIRK. The bee venom toxin tertiapin is a nanomolar afﬁnityGIRK
antagonist that also inhibits Kir1.1 (Jin and Lu, 1998; Kitamura
et al., 2000). Hashimoto et al. (2006) demonstrated that adminis-
tration of tertiapin to cannulated dogs terminated induced atrial
ﬁbrillation, providing some of the ﬁrst experimental evidence that
GIRK is a target for anti-arrhythmic therapeutics (Hashimoto
et al., 2006). Nissan Chemical Industries developed a benzopyrene
derivative, termed NIP-142, which inhibits Kir3.1/3.4 GIRK chan-
nels with sub-micromolar afﬁnity and the cardiac Kv1.5 delayed
rectiﬁer current with equal potency (Matsuda et al., 2006; Tanaka
and Hashimoto, 2007). NIP-142 has shown efﬁcacy in terminat-
ing induced atrial ﬁbrillation in dogs, but it is unknown whether
the improvement in sinus rhythm is due to inhibition of GIRK,
Kv1.5, or both. However, the low nanomolar inhibitor NTC-801,
which is highly selective for GIRK over other cardiac channels, was
shown recently to be effective in severalmodels of atrial ﬁbrillation
(Machida et al., 2011).
In an effort to further expand the molecular pharmacology of
GIRK, we employed a Tl+ ﬂux-based ﬂuorescence assay to screen
a Kir1.1 inhibitor focus library for antagonists of GIRK. One com-
pound termed VU573 was found to preferentially inhibit GIRK
(cardiac and neuronal forms), Kir2.3 and Kir7.1 over Kir1.1 and
Kir2.1. We anticipate that VU573 and its analogs will be useful for
investigating the physiology and structure–function relationships
of inward rectiﬁer potassium channels.
MATERIALS AND METHODS
EXPRESSION VECTORS
Plasmids used in this study are from the following sources:
rat Kir1.1 (NM_017023; Chun Jiang, Georgia State Univer-
sity, Atlanta, GA, USA), human Kir2.1 (NM_000891.2; Al
George, Vanderbilt University School of Medicine, Nashville,
TN, USA), human Kir7.1 (NM_002242.2; David Clapham, Har-
vard Medical School, Cambridge, MA, USA). Human Kir1.1
(NM_000220), Kir3.1 (NM_002239.2), Kir3.2 (NM_002240.2),
Kir3.4 (NM_000890.3), and Kir2.3 (NM_152868) were purchased
from OriGene Technologies (Rockville, MD, USA). The M125R
mutant of Kir7.1was created using theQuickChange Site-Directed
Mutagenesis Kit (Agilent Technologies). The open reading frame
of Kir7.1 was fully sequenced to ensure that no spuriousmutations
were introduced during mutation of the intended codon.
CELL LINES
MonoclonalmGluR8/GIRK/HEKcells stably expressingKir3.1/3.2,
the M4 muscarinic receptor and rat mGlu8a were cultured as
described previously (Niswender et al., 2008). Polyclonal stable
T-REx-HEK-293 cell lines expressing Kir2.3 and Kir7.1-M125R
under the control of a tetracycline-inducible promoter were estab-
lished essentially as described in detail elsewhere (Fallen et al.,
2009; Lewis et al., 2009). Monoclonal Kir2.3 cell lines were iso-
lated through limiting dilution in 384-well plates and testing
for tetracycline-inducible Tl+ ﬂux, as described below. Poly-
clonal Kir7.1-M125R cells were used in this study. The develop-
ment of monoclonal C1 T-REx-HEK-293 cells expressing Kir1.1
(S44D)was described previously (Lewis et al., 2009). T-REx-HEK-
293 lines were cultured in DMEM growth medium containing
10% FBS, 50U/mL Penicillin, 50μg/mL Streptomycin, 5μg/mL
Blasticidin S, and 250μg/mL Hygromycin.
TWO-ELECTRODE VOLTAGE-CLAMP ANALYSIS
Stage V–VI oocytes were isolated from gravid Xenopus laevis frogs
using sterile surgical techniques under tricaine anesthesia. All
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methods were in accordance with the guidelines for the use of lab-
oratory animals of Vanderbilt University School of Medicine. The
oocyte follicle layer was removed by manual dissection following
enzymatic treatment with 1mg/mL collagenase (Type 1A Sigma)
dissolved in calcium-free OR-2 of the following composition (in
mM): 82.5 NaCl, 2 KCl, 1 MgCl2, 5 HEPES, with pH 7.5 adjusted
with NaOH. Oocytes were allowed to recover overnight at 16˚C in
modiﬁed L-15 media containing gentamicin sulfate (25mg/mL).
pcDNA3.1(+) vectors carrying Kir1.1, human Kir2.1, 2.3, and
7.1 cDNA were used to synthesize channel cRNA from a T7 RNA
polymerase and nucleotides provided in the mMESSAGE mMA-
CHINE kit (Ambion, Austin, TX, USA) after linearization of the
expression constructs. cRNA was puriﬁed by LiCl precipitation,
diluted in RNAase-free water and used for injections. The oocytes
were injected with 0.5–10 ng of cRNA of Kir1.1, Kir2.1, Kir2.3,
and Kir7.1 using a Drummond digital microdispenser. Oocytes
were incubated at 16˚C in modiﬁed L-15 for 24–72 h prior to Kir
channel recordings.
Whole-cell currents were recorded from Xenopus oocytes
injected with Kir channel cRNA using the two-electrode voltage-
clamp (TEVC) technique. Current and voltage commands were
generated with a GeneClamp 600 ampliﬁer, a Digidata 1200 A/D
converter, and pCLAMP 8.0 software (Molecular Devices, Sunny-
vale, CA, USA). The bath was actively clamped to 0mV using a
VG-2A bath clamp (Molecular Devices). Electrodes pulled from
borosilicate glass (Sutter Instruments, Novato, CA, USA) using a
PP-830 vertical puller (Narishige International, Narishige, Japan)
had resistances of 0.5–5.0MΩ when ﬁlled with 3MKCl. The stan-
dard bath solution contained (in mM): 85 NaCl, 5 KCl, 10 HEPES,
2MgCl2, pH 7.4 withNaOH.After achieving stable current ampli-
tude, VU573 was applied continuously. This was followed by
application of the non-speciﬁc potassium channel blocker barium.
ForKir current recordings, cells were voltage-clamped and stepped
every 5 s from a holding potential of −70 to −100mV for 200ms,
then ramped at a rate of 1.6mV/ms to 60mV before return-
ing to −80mV. All recordings were made at room temperature
(20–23˚C).
WHOLE-CELL PATCH CLAMP ELECTROPHYSIOLOGY
T-REx-HEK-293-Kir2.3 cells were patch clamped after overnight
induction with tetracycline (1μg/mL). GIRK (Kir3.1/3.2) and
wild type Kir7.1 were studied in HEK-293 cells transiently
co-transfected with the respective channel expression vectors
and pcDNA3.1-EGFP (transfection marker) using Lipofectamine
LTX/Plus reagent according to manufacturer’s protocol (Invit-
rogen, Carlsbad, CA, USA). The standard intracellular solution
contained 135mM KCl, 2mM MgCl2, 1mM EGTA, 10mM
HEPES-free acid, and 2mM Na2 ATP (Roche), pH 7.3, adjusted
to 275mOsmol/kg with sucrose. For Kir2.3 recordings, MgCl2
was reduced to 1mM to prevent channel rundown (Chuang
et al., 1997). The standard bath solution contained 135mM NaCl,
5mM KCl, 2mM CaCl2, 1mM MgCl2, 5mM glucose, and 10mM
HEPES-free acid, pH 7.4, 290mOsmol/kg. In some experiments, a
high-K+ bath was used that contained 90mM NaCl, 50mM KCl,
2mM CaCl2, 1mM MgCl2, 5mM glucose, and 10mM HEPES-
free acid, pH 7.4, 290mMmOsmol/kg. Kir current recordings
were collected as previously described (Bhave et al., 2011). After
achieving stable whole-cell currents, VU573 was applied inter-
mittently or continuously for 2–10min, followed by application
of 2mM BaCl2. Data acquisition and analysis were performed
using pClamp 9.2 software (Molecular Devices). All recordings
were made at room temperature (20–23˚C).
TEST COMPOUND AND STIMULUS PLATE PREPARATION
Compound master antagonist plates were created by serial dilut-
ing compounds 1:3 from 10mM stock in 100% DMSO using the
BRAVO liquid handler (Agilent Technologies, Santa Clara, CA,
USA). Assay daughter plates were created using the ECHO 555
liquid hander (Labcyte, Sunnyvale, CA, USA), transferring 240 nL
from the master plate to the daughter plate for each well followed
by addition of 40μL of assay buffer resulting in antagonist com-
pound concentration–response curves (CRC) starting at 60μM
(2× ﬁnal concentration). Glutamate was diluted in Tl+ buffer
[125mM sodium bicarbonate (added fresh the morning of the
experiment), 1mM magnesium sulfate, 1.8mM calcium sulfate,
5mM glucose, 12mM Tl+ sulfate, and 10mM HEPES, pH 7.3] at
5× the ﬁnal concentration to be assayed.
KINETIC IMAGING, DATA ANALYSIS, AND STATISTICS
Cells were loaded with the Tl+ sensitive ﬂuorescent dye FluoZin-2
and plated in clear-bottom 384-well plates essentially as described
previously (Lewis et al., 2009; Bhave et al., 2011). Cell plates and
daughter compound plates were loaded onto a kinetic imaging
plate reader (FDSS 6000; Hamamatsu Corporation, Bridgewater,
NJ, USA). All recordings were made at room temperature (20–
23˚C). Appropriate baseline readings were taken (10 images at
1Hz; excitation, 470± 20 nm; emission, 540± 30 nm) and 20μL
test compounds were added followed by 50 images at 1Hz addi-
tional baseline. Following a 20-min incubation period, baseline
readings were taken for 30 s followed by addition of 10μL Glu-
tamate at an EC80 concentration. An additional 170 images were
taken at 1Hz. Glutamate EC80 concentration was determined the
day of the assay.
Data were analyzed using Excel (Microsoft Corp, Redmond,
WA, USA). Raw data were opened in Excel and each data point in
a given tracewas divided by the ﬁrst data point from that trace (sta-
tic ratio). For experiments in which antagonists were added, data
were again normalized by dividing each point by the ﬂuorescence
value immediately before the glutamate addition to correct for any
subtle differences in the baseline traces after the compound incu-
bation period. The slope of the ﬂuorescence increase beginning 5 s
after Tl+/glutamate addition and ending 15 s after Tl+/glutamate
addition was calculated. The data were then plotted in Prism soft-
ware (GraphPad Software, San Diego, CA, USA) to generate CRC
after correcting for the slope values determined for baseline wave-
forms generated in the presence of vehicle controls. Potencies were
calculated from ﬁts using a four-parameter logistic equation.
CHEMICAL SYNTHESIS
General
All NMR spectra were recorded on a 400-MHz AMX Bruker
NMR spectrometer. 1H chemical shifts are reported in δ values
in part per million downﬁeld with the deuterated solvent as
the internal standard. Data are reported as follows: chemi-
cal shift, multiplicity (s= singlet, d= doublet, t= triplet, q=
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SCHEME 1 | Synthesis of theVU573 scaffold.
quartet, br= broad, m=multiplet), integration, coupling con-
stant (Hz). Low resolution mass spectra were obtained on
an Agilent 1200 series 6130 mass spectrometer with electro-
spray ionization. High-resolution mass spectra were recorded
on a Waters Q-TOF API-US plus Acquity system with electro-
spray ionization. Analytical thin layer chromatography was per-
formed on EM Reagent 0.25mm silica gel 60-F plates. Samples
were analyzed for ≥95% purity using LC-UV/Vis-MS. Analyt-
ical HPLC was performed on an Agilent 1200 series with UV
detection at 214 and 254 nm along with ELSD detection. LC/MS:
method 1= J-Sphere80-C18, 3.0mm× 50mm, 4.1min gra-
dient, 5%[0.05%TFA/CH3CN]:95%[0.05%TFA/H2O] to 100%
[0.05%TFA/CH3CN]; method 2=Phenomenex-C18, 2.1mm×
30mm, 2min gradient, 7%[0.1%TFA/CH3CN]:93%[0.1%TFA/
H2O] to 100%[0.1%TFA/CH3CN]; method 3=Phenomenex-
C18, 2.1mm× 30mm, 1min gradient, 7%[0.1%TFA/CH3CN]:
93%[0.1%TFA/H2O] to 95%[0.1%TFA/CH3CN]. Preparative
puriﬁcation was performed on a custom HP1100 puriﬁcation
system (Leister et al., 2003)with collection triggered bymass detec-
tion. Solvents for extraction, washing, and chromatography were
HPLC grade. All reagents were purchased from Aldrich Chemical
Co. and were used without puriﬁcation.
Reagents. Substituted phenols were purchased from vari-
ous commercial sources, 2-Amino-1-benzylbenzimidazole and
2-Amino-1-methylbenzimidazole were purchased from Acros
Organics. 1-(4-Chlorophenylmethyl)-2-aminobenzimidazole was
made using published procedures (Caroti et al., 1986).
General synthetic procedure
The desired phenol (2mmol) was dissolved in 0.4mL NaOH
(5M) and then treated with epichlorohydrin (0.32mL, 3.7mmol;
Scheme 1). The mixture was heated in a Biotage Initiator
microwave reactor at 100˚C for a 15-min period. The reaction was
cooled to ambient temperature and dilutedwith dichloromethane.
The aqueous layer was removed and the organic layer extracted
with water. The mixture was dried and solvent removed under
reduced pressure. The crude mixture was then treated with the
desired 2-aminobenzimidazole (3mL, 0.2mmol, 0.7M MeOH)
dissolved in methanol (Scheme 1). The mixture was allowed
to stir for 4 days at ambient temperature. The solvent was
removed under reduced pressure and the residue was diluted with
dichloromethane. The mixture was extracted with water, dried,
and concentrated under reduced pressure. The crude was puri-
ﬁed using reverse phase chromatography (C18, Acetonitrile/H2O
0.1% TFA).
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(p-tolyloxy)propan-2-ol (1). Purchased from ChemBridge.
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(2,4-dichlorophenoxy)propan-2-ol (2).
LCMS: Rt= 1.41min.,>98%, m/z= 443 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-chlorophenoxy)propan-2-ol (3).
LCMS: Rt= 1.38min.,>98%, m/z= 408 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(m-tolyloxy)propan-2-ol (4).
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Purchased from InterBioScreen.
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
phenoxypropan-2-ol (5).
Purchased from ChemBridge.
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(o-tolyloxy)propan-2-ol (6).
Purchased from ChemBridge.
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(3,5-diﬂuorophenoxy)propan-2-ol (7).
LCMS: Rt= 1.05min.,>98%, m/z= 410 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-isopropylphenoxy)propan-2-ol (8).
LCMS: Rt= 1.14min.,>98%, m/z= 416 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
morpholinopropan-2-ol (9).
LCMS: Rt= 0.67min.,>98%, m/z= 367 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-benzylphenoxy)propan-2-ol (10).
LCMS: Rt= 1.19min.,>98%, m/z= 464 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-(benzyloxy)phenoxy)propan-2-ol (11).
LCMS: Rt= 1.16min.,>98%, m/z= 480 [M+H].
4-(3-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-
yl)-2-hydroxypropoxy)benzonitrile (12).
LCMS: Rt= 1.00min.,>98%, m/z= 399 [M+H].
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1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-methoxyphenoxy)propan-2-ol (13).
LCMS: Rt= 1.00min.,>98%, m/z= 404 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(3-methoxyphenoxy)propan-2-ol (14).
LCMS: Rt= 1.01min.,>98%, m/z= 404 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(2-chlorophenoxy)propan-2-ol (15).
LCMS: Rt= 1.08min., 90%, m/z= 408 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(4-bromo-3-methylphenoxy)propan-2-ol (16).
LCMS: Rt= 1.13min.,>98%, m/z= 466 [M+H].
3-(3-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-
yl)-2-hydroxypropoxy)-4-ﬂuorobenzonitrile (17).
LCMS: Rt= 0.99min.,>98%, m/z= 417 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(3-chlorophenoxy)propan-2-ol (18).
LCMS: Rt= 1.06min.,>98%, m/z= 408 [M+H].
3-(3-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-
yl)-2-hydroxypropoxy)-5-ﬂuorobenzonitrile (19).
LCMS: Rt= 1.00min., 90%, m/z= 417 [M+H].
1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-3-
(3,5-dimethylphenoxy)propan-2-ol (20).
LCMS: Rt= 1.10min., 93%, m/z= 402 [M+H].
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1-(3-benzyl-2-imino-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-
3-(2-methoxyphenoxy)propan-2-ol (21).
LCMS: Rt= 0.98min.,>98%, m/z= 404 [M+H].
1-(3-(4-chlorobenzyl)-2-imino-2,3-dihydro-1H -benzo[d]
imidazol-1-yl)-3-phenoxypropan-2-ol (22).
LCMS: Rt= 1.33min., 87%, m/z= 408 [M+H].
1-(3-(4-chlorobenzyl)-2-imino-2,3-dihydro-1H -benzo[d]
imidazol-1-yl)-3-(4-chlorophenoxy)propan-2-ol (23).
LCMS: Rt= 1.38min.,>98%, m/z= 442 [M+H].
1-(2-imino-3-(3-methoxybenzyl)-2,3-dihydro-1H -benzo[d]
imidazol-1-yl)-3-(p-tolyloxy)propan-2-ol (24).
LCMS: Rt= 1.05min.,>98%, m/z= 418 [M+H].
1-(2-imino-3-methyl-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-
3-(p-tolyloxy)propan-2-ol (25).
LCMS: Rt= 0.91min.,>98%, m/z= 312 [M+H].
1-(2-imino-3-methyl-2,3-dihydro-1H -benzo[d]imidazol-1-yl)-
3-(4-(triﬂuoromethyl)phenoxy)propan-2-ol (26).
LCMS: Rt= 1.11min.,>98%, m/z= 442 [M+H].
RESULTS
VU573: A WEAK Kir1.1 INHIBITOR THAT PREFERENTIALLY INHIBITS GIRK
We recently performed a high-throughput screen (HTS) for small-
molecule modulators of Kir1.1 (Lewis et al., 2009), the founding
member of the inward rectiﬁer potassium (Kir) channel family
(Ho et al., 1993; Zhou et al., 1994) and putative diuretic target
(Simon et al., 1996; Ji et al., 2008; Pasternak et al., 2010). A focused
library of reproducibly active inhibitors was assembled from the
primary screen, with the goal of mining the library for antago-
nists of other inward rectiﬁers. As noted in the Introduction, a
growing body of evidence suggests that GIRK channels expressed
in atrial cardiomyocytes may represent a viable drug target for
the treatment of atrial ﬁbrillation. Given the paucity of potent
and selective small-molecule inhibitors of GIRK and therapeutic
interest in the channel, we screened the focus library for GIRK
modulators using a Tl+ ﬂux-based ﬂuorescence assay developed
recently at Vanderbilt (Niswender et al., 2008). The assay reports
Tl+ ﬂux through heteromeric Kir3.1/3.2 channels co-expressed in
HEK-293 cells with the group III metabotropic glutamate recep-
tor mGluR8. Intracellular Tl+ concentration is reported using the
commercially available Tl+-sensitive ﬂuorescent dye FluoZin-2.
As shown in Figure 1A, glutamate addition dose-dependently
increased Tl+ ﬂux as GIRK channels are activated by mGluR8
stimulation. The focused library was screened at a single concen-
tration of 10μM using an 80% maximally effective concentration
(EC80) of glutamate. Several compounds were identiﬁed that pref-
erentially inhibited GIRK over Kir1.1 (data not shown). One of
these compounds, termed VU573, was selected for further study.
The chemical structure of VU573 is shown in the inset of
Figure 1C. The potency of VU573 was evaluated in 11-point
CRC using an EC80 of glutamate to activate GIRK. As shown in
Figure 1B, VU573 inhibited GIRK-dependent Tl+ ﬂux in a dose-
dependent manner with a 50% inhibition concentration (IC50) of
approximately 1.9μM (Figure 1C).
To verify that VU573 is a more potent inhibitor of GIRK
than Kir1.1, a full VU573 CRC was generated using an estab-
lished Tl+ ﬂux assay for Kir1.1 (Lewis et al., 2009; Bhave
et al., 2011). The assay employs an inducible system in which
Kir1.1 is expressed from a tetracycline-regulatable promoter. As
shown in Figure 1D, extracellular Tl+ addition produced a dra-
matic increase in FluoZin-2 ﬂuorescence in cells cultured with
www.frontiersin.org November 2011 | Volume 2 | Article 75 | 7
Raphemot et al. Inhibitor of Kir2.3, Kir3.X, and Kir7.1
FIGURE 1 |VU573 inhibits mGluR8-activated Kir3.1/3.2 channel activity
in thallium flux assays. (A) Representative FluoZin-2 ﬂuorescence traces
recorded from HEK-293 cells stably expressing mGluR8 and Kir3.1/3.2
before and after co-application of thallium and different doses of glutamate
(shaded box). From an 11-point glutamate concentration–response curve
(not shown), the glutamate concentration evoking approximately 80% (EC80)
of the maximal response (ECmax) was determined and used for subsequent
experiments. (B) Representative traces for changes of Tl+-induced FluoZin-2
ﬂuorescence following 20min pre-treatment of cells with the indicated
concentrations of VU573 and subsequent thallium and glutamate-EC80
addition (shaded box). (C) Mean±SEM concentration–response curve for
VU573-dependent inhibition of Kir3.1/3.2 (n=3). The chemical structure of
VU573 is shown in the inset. (D) Representative FluoZin-2 ﬂuorescence
traces recorded from monoclonal Kir1.1-S44D expressing cells cultured
overnight in absence (−Tet) or presence (+Tet) of Tetracycline. (E)
Representative traces for changes of Tl+-induced FluoZin-2 ﬂuorescence
following pre-treatment of cells with the indicated concentrations of VU573
and then exposed to thallium (shaded box). (F) Mean±SEM
concentration–response curve for VU573-dependent inhibition of
Kir1.1-S44D (n=3).
tetracycline, but not in uninduced cells. Thus,most of the Tl+ ﬂux
in tetracycline-induced cells occurs through Kir1.1. VU573 exhib-
ited weak yet dose-dependent inhibition of Kir1.1 (Figure 1F),
with an IC50 of approximately 19μM. Whole-cell patch clamp
experiments conﬁrmed that 20μM VU573 inhibited Kir1.1 by
49.5± 0.03% (n = 5). Thus, VU573 is a preferential inhibitor of
GIRK over Kir1.1.
VU573 SHOWS PREFERENCE FOR KIR2.3, GIRK, AND KIR7.1 OVER KIR1.1
AND KIR2.1
To further assess the selectivity of VU573, several members of
the Kir channel family were expressed in Xenopus oocytes and
screened for VU573 sensitivity using the TEVC technique. We
ﬁrst tested whether VU573 discriminates between Kir3.1/3.2 and
Kir3.1/3.4 channels, the predominant heterotetrameric forms of
GIRK found in the nervous system and heart, respectively (Hibino
et al., 2010). Figure 2A illustrates a typical experiment performed
on an oocyte co-injected with cRNA encoding Kir3.1 and Kir3.2.
Current recorded at −80mV is shown as a function of time. The
oocyte was initially bathed in a potassium-free (0K) solution and
then switched to one containing 90mM K+ (90K) to activate
GIRK. The dramatic increase in inward current in the presence of
90K buffer was not observed in water-injected oocytes (data not
shown) and therefore largely reﬂects current through Kir3.1/3.2
channels. Bath application of 10μM VU573 inhibited GIRK cur-
rent by approximately 50%, which was signiﬁcantly lower than
expected from Tl+ ﬂux experiments (Figure 1C). The residual
current was blocked by Ba2+. Figure 2F shows mean± SEM per-
centage block of Kir3.1/3.2 and Kir3.1/3.4 channels by 1, 10, and
25μM VU573 or Ba2+. The mean± SEM time constant (τ) for
inhibition of Kir3.1/3.2 and Kir3.1/3.4 currents by 25μM VU573
were 28± 4 s (n = 6) and 27± 5 s (n = 6), respectively. There were
no signiﬁcant (P > 0.05) differences in the degree of VU573-
dependent block of Kir3.1/3.2 and Kir3.1/3.4 channels at any of
the concentrations.
GIRK channels are co-expressed with other members of the
Kir channel family in a tissue- and cell type-speciﬁc man-
ner. As noted in the Introduction, there is growing evidence
that inhibitors of cardiac GIRK channels may be therapeu-
tically beneﬁcial in patients with atrial ﬁbrillation. However,
Kir2.1 and Kir2.3 are also expressed in the heart (Hibino et al.,
2010) and therefore represent potential off-targets for VU573
actions. GIRK, Kir2.1, and Kir2.3 are also co-expressed in var-
ious brain regions, as is one of the newest Kir channel family
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FIGURE 2 | Effect ofVU573 on Kir channels expressed in oocytes. (A)
Representative Kir3.1/3.2 current traces recorded from an oocyte using the
two-electrode voltage-clamp technique. Oocytes were initially bathed in a
potassium-free (0K) solution and then switched to one containing 90mM
potassium (90K) to activate Kir3.1/3.2. After reaching a steady-state, the
oocyte was exposed to 10μMVU573 (in 90K) bath to inhibit Kir3.1/3.2.
Residual Kir3.1/3.2 currents were inhibited with 2mM barium (Ba2+). A ﬁnal
switch back to 0K was used to measure leak current at the end of each
experiment. Representative whole-cell current traces recorded from oocytes
expressing respectively (B) Kir1.1, (C) Kir2.1, (D) Kir2.3, and (E) Kir7.1 before
and after application of 50μMVU573. Residual Kir currents were inhibited
with 2mM barium (Ba2+). (F) Mean±SEM percent inhibition of current
evoked by Kir3.1/3.2, Kir3.1/3.4, Kir1.1, Kir2.1, Kir2.3, and Kir7.1 with the
indicated concentrations of VU573 () or Ba2+ () n=4–6).
members, Kir7.1 (Krapivinsky et al., 1998). We therefore deter-
mined whether VU573 inhibits any of these channels expressed in
Xenopus oocytes. Kir1.1 was also expressed to conﬁrm the results
from Tl+ ﬂux and patch clamp experiments.
Representative TEVC recordings from oocytes expressing
Kir1.1, Kir2.1, Kir2.3, or Kir7.1 are shown in Figures 2B–E.
The oocytes were voltage-clamped at −75mV and stepped for
200ms every 5 s to −120mV to evoke inward current. The cur-
rent amplitude at −120mV is shown as a function of time.
Barium was again used at the end of each experiment as a con-
trol blocker. Consistent with the Tl+ ﬂux data showing greater
potency toward GIRK than Kir1.1, 50μMVU573 inhibited Kir1.1
by only 4.3± 1.7%with a time constant of 95± 15 s (n = 8). Kir2.1
was also relatively insensitive to VU573, and the time constant
was very slow (τ= 735± 85 s; n = 4; Figure 2C). After 25min
of constant bath perfusion, 50μM VU573 inhibited Kir2.1 by
only 30.2± 9.4%. In contrast, Kir2.3 was inhibited comparatively
quickly (τ = 154± 32 s) by 80.9± 5.0% (n = 7). Similarly, Kir7.1
was inhibited by 66.0± 6% with a rapid time constant of 38± 6 s
(n = 8).
PATCH CLAMP ANALYSIS OF VU573 POTENCY IN MAMMALIAN CELLS
GIRK is inhibited by VU573 with an IC50 of approximately 2μM
in Tl+ ﬂux assays in HEK-293 (Figure 1) cells and 10μM in TEVC
experiments in oocytes (Figure 2). To determine if the discrep-
ancy is due to the expression system or assay type,whole-cell patch
clamp techniqueswere used to assess the potency ofVU573 toward
Kir3.1/3.2 GIRK channels expressed in HEK-293 cells. The cells
were voltage-clamped at a holding potential of −75mV and then
stepped to−120mV for 200ms, after which themembrane poten-
tial was ramped between−120 and 120mV at a rate of 2.4mV/ms.
As shown in Figure 3B, GIRK activity was low in the presence of
5mM extracellular K+ (5K), but increased upon elevation of bath
K+ to 50mM (50K), paralleling the behavior of GIRK observed in
oocytes. Consistent with Tl+ ﬂux data (Figure 1C), bath applica-
tion of 30μM VU573 led to a near complete inhibition of GIRK.
As shown in the voltage ramp experiments in Figure 3A, VU573
inhibited GIRK across all potentials tested. The residual current
was inhibited by barium (Ba2+; Figure 3B). The mean± SEM
time constant of inhibition was 16± 1 s (n = 5). A ﬁt of the CRC
data (Figure 3C) from patch clamp experiments yielded an IC50
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FIGURE 3 |VU573-dependent inhibition of Kir3.1/3.2, Kir2.3, and Kir7.1
channel activity expressed in HEK-293 cells. (A,D,G) Representative
whole-cell Kir3.1/3.2, Kir2.3, and Kir7.1 current traces recorded from
transfected HEK-293 cells. The cell was voltage ramped every 5 s
between −120 and 120mV for 200ms from a holding potential of −75mV.
Normalized Kir3.1/3.2, Kir2.3, and Kir7.1 currents recorded before (black
line) and after reaching steady-state inhibition by 30μMVU573 (gray line)
are shown. (B,E,H) Representative time course traces of
VU573-dependent inhibition of Kir3.1/3.2, Kir2.3, and Kir7.1 by 30μM
VU573 using the protocol described above. After achieving whole-cell
access, the current was allowed to stabilize before adding 30μMVU573
and then 2mM barium (Ba2+) to inhibit channel activity. (C,F,I)
Mean±SEM concentration–response curves for Kir3.1/3.2 (n=4–7),
Kir2.3 (n=4–6), and Kir7.1 (n=4–7), respectively.
of 1.3μM, which is very near that derived from Tl+ ﬂux assays
(Figure 1C).
We extended our patch clamp experiments to include Kir2.3
and Kir7.1 due to their strong inhibition by VU573 in oocytes
(Figure 2F). A monoclonal stable T-REx-HEK-293 cell line
expressing Kir2.3 under the control of a tetracycline-inducible
promoter was patch clamped following overnight induction with
tetracycline. Kir7.1 was studied in transiently transfected HEK-
293 cells (see Materials and Methods). The cells were subjected to
the same voltage ramp protocol described above for GIRK. Steady-
state Kir2.3 and Kir7.1 currents recorded before (black line) and
after (gray line) bath application of 30μM VU573 are shown in
Figures 3D,G, respectively. Both channels were inhibited with a
rapid time course (Figures 3E,H) and IC50 values of approximately
1μM (Figures 3F,I). The mean± SEM time constants for inhibi-
tion of Kir2.3 and Kir7.1 were 23± 2 and 14± 2 s, respectively
(n = 4 each).
DEVELOPMENT OF Tl+ FLUX ASSAYS FOR Kir2.3 AND Kir7.1-M125R
We next set out to employ medicinal chemistry in an effort to
improve the potency and selectivity of VU573 toward GIRK,
Kir2.3, and Kir7.1. Conventional electrophysiological methods
are too slow and labor intensive to support a robust medici-
nal chemistry campaign, leading us to establish high-throughput
Tl+ ﬂux assays for Kir2.3 and Kir7.1.As shown in Figure 4A,
robust tetracycline-inducible Tl+ ﬂux was observed in mono-
clonal stable T-REx-HEK-293 expressing Kir2.3. VU573 dose-
dependently inhibited Tl+ ﬂux through Kir2.3 with an IC50 of
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FIGURE 4 | Development of a thallium flux assay for Kir2.3. (A)Thallium
ﬂux-dependent FluoZin-2 ﬂuorescence recorded from monoclonal Kir2.3
T-REx-HEK-293 cells cultured overnight in absence (−Tet) or presence (+Tet) of
Tetracycline. The ﬂuorescence emission was recorded before and after the
addition of extracellular thallium (shaded box). (B) Representative traces for
changes of Tl+-induced FluoZin-2 ﬂuorescence following 20min pre-treatment
of cells with the indicated concentrations of VU573. (C) CRC for
VU573-dependent inhibition of Kir2.3 activity. Values are mean±SEM (n=3).
A ﬁt of the CRC with a single-site four-parameter logistic function yielded IC50
of 4.7.
4.7μM (Figures 4B,C), a value that is reasonably close to that
derived from patch clamp experiments (Figure 3F).
In contrast, despite numerous attempts on multiple polyclonal
and monoclonal cell lines, we were unable to detect Tl+ ﬂux
through Kir7.1. Western blot analysis revealed that this was not
due to lack of channel protein expression (data not shown), sug-
gesting that other channel properties were responsible. Kir7.1 is
unique among Kir channels in that it has a very small unitary
conductance, which has been estimated from noise analysis to be
on the order of 50 femptoSiemens (fS; Krapivinsky et al., 1998).
We reasoned that this could keep Tl+ ﬂux through Kir7.1 below
the limit of detection of FluoZin-2. The small conductance of the
channel is due at least in part to a non-conserved Methionine
(M) residue at position 125 located in the pore. Mutation of the
residue to Arginine (R),which occupies the homologous position
in all other Kir channels (not shown), has no effect on protein
expression or targeting to the plasmamembrane, but increases the
single-channel conductance by approximately 20-fold (Krapivin-
sky et al., 1998). We therefore wondered if the M125R mutation
could enable measurement of Tl+ ﬂux using FluoZin-2. As shown
in Figure 5B, tetracycline-induced robust Tl+ ﬂux in polyclonal
stable T-REx-HEK-293 cells expressing Kir7.1-M125R. VU573
induced concentration-dependent inhibition of Tl+ ﬂux with an
IC50 of 4.9μM (Figures 5C,D). The good correlation between
IC50 values from patch clamp and Tl+ ﬂux experiments and the
fact that the M125R mutation had no effect on the sensitivity to
VU573 in patch clamp experiments (Figure 5A) indicated that the
Kir7.1-M125R assays could be used as a screening tool to support
medicinal chemistry efforts for VU573.
SYNTHESIS AND STRUCTURE–ACTIVITY RELATIONSHIPS OF VU573
ANALOGS
Leadoptimization efforts directed atVU573 to improve its potency
and selectivity toward Kir2.3, GIRK, and Kir7.1 were initiated
by conserving the benzyl moiety and substituting the R group
(Table 1). Structure–activity relationships (SAR) revealed few
analogs with channel selectivity. Replacement of the phenoxymoi-
ety with a morpholino group to the VU573 scaffold resulted in
FIGURE 5 | Development of a thallium flux assay for Kir7.1 (M125R).
(A) Mean±SEM % inhibition of wild type (closed bars; n=6–7) or M125R
mutant (open bars; n=4–6) Kir7.1 by the indicated concentration of
VU573.Note that the wild type data are reproduced from Figure 3.
(B)Thallium ﬂux-dependent FluoZin-2 ﬂuorescence recorded from
polyclonalKir7.1 (M125R) T-REx-HEK-293 cells cultured overnight in absence
(−Tet) or presence (+Tet) of Tetracycline. The ﬂuorescence emission was
recorded before and after the addition of extracellular thallium (shaded box).
(C) Representative traces for changes ofTl+-induced FluoZin-2 ﬂuorescence
following 20min pre-treatment of cells with the indicated concentrations of
VU573. (D) CRC for VU573-dependent inhibition of Kir2.3 activity. Values are
mean±SEM (n=3). A ﬁt of the CRC with a single-site four-parameter
logistic function yielded IC50 of 4.9μM.
compound (9), which lost activity (IC50 values> 100μM) for
Kir7.1 and Kir1.1. The IC50 values for Kir2.3 and GIRK were
24 and 15.3μM, respectively. Substitution of the R group of the
VU573 scaffold with a phenoxy benzyloxy functional group led to
an analog (11), which was equipotent for Kir2.3 and GIRK, but
loss activity toward Kir7.1 (IC50 values> 100μM). An alternate
functional group for the VU573 scaffold, a 4-cyanophenyl (12),
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Table 1 | Structure–activity relationships and lead optimization summary.
Cmpd R VU#/Barcode IC50 (μM)
Kir2.3 Kir7.1 GIRK Kir1.1
1 VU0160573-1/IC4X 4.15±0.35 4.77±2.89 2.17±0.40 10.8±3.8
2 VU0403134-1/IC3Y 5.33±2.08 4.73±2.57 3.20±0.71 7.07±2.30
3 VU0403131-1/IC58 4.20±1.25 5.17±1.89 2.90±1.10 6.57±3.80
4 VU0340260-1/IC38 7.53±2.34 8.00±3.86 4.95±1.80 11.2±2.8
5 VU0026784-1/IC3L 3.43±0.67 4.47±2.40 1.95±0.49 11.7±4.1
6 VU0288495-1/IC39 5.33±1.70 4.10±1.93 1.95±0.07 11.9±2.2
7 VU0451348-1/R6P 3.53±1.33 4.20±0.95 1.40±0.35 7.57±2.20
8 VU0451344-1/R80 5.03±1.96 6.03±1.60 3.37±0.70 6.77±1.70
(Continued)
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Table 1 | Continued
Cmpd R VU#/Barcode IC50 (μM)
Kir2.3 Kir7.1 GIRK Kir1.1
9 VU0451342-1/R70 24.0±10.4 >100 15.3±0.6 >100
10 VU0451341-1/R7M 2.80±0.99 6.07±2.71 3.83±1.10 6.13±0.23
11 VU0451340-1/R5C 2.33±0.68 >100 3.17±0.86 5.23±0.59
12 VU0451339-1/R56 11.3±1.2 19.7±7.4 5.27±0.40 15.7±2.1
13 VU0066224-6/R7N 3.87±1.40 6.70±1.39 1.50±0.44 12.7±1.2
14 VU0451336-1/R5B 3.13±1.45 3.47±0.67 1.43±0.25 10.1±2.9
15 VU0451333-1/R5X 4.95±1.34 5.33±2.91 2.77±0.60 8.60±1.20
16 VU0451337-1/R5K 5.10±1.27 6.10±3.12 3.43±0.21 8.53±1.70
17 VU0451332-1/R7B 5.30±1.56 4.33±1.33 1.40±0.30 8.27±0.29
(Continued)
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Table 1 | Continued
Cmpd R VU#/Barcode IC50 (μM)
Kir2.3 Kir7.1 GIRK Kir1.1
18 VU0451338-1/R71 4.45±0.92 5.63±2.24 2.83±0.42 11.7±2.1
19 VU0451330-1/R6J 7.15±0.71 8.27±2.37 1.93±0.21 14.3±1.5
20 VU0451331-1/RKN 3.65±0.21 3.03±0.68 4.33±0.68 16.0±2.0
21 VU0451846-2/R87 3.60±0.28 8.50±2.18 5.13±1.60 19.3±1.5
Cmpd R R′ VU#/Barcode IC50 (μM)
Kir2.3 Kir7.1 GIRK Kir1.1
22 VU0401333-1/IC4L 7.20±1.73 8.93±3.53 4.80±1.10 14.7±2.1
23 VU0403132-1/IC48 5.70±3.18 19.5±28.2 3.35±0.92 6.53±3.90
24 VU0451343-1/RJ4 2.80±0.89 3.00±0.87 4.20±0.69 13.7±4.4
25 VU0451335-1/R5P 16.5±0.7 25.3±8.5 12.3±2.5 13.0±2.6
(Continued)
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Table 1 | Continued
Cmpd R R′ VU#/Barcode IC50 (μM)
Kir2.3 Kir7.1 GIRK Kir1.1
26 VU0451334-1/R7L 4.90±0.14 5.20±1.82 2.87±0.31 6.97±2.00
Summary of structure–activity relationships of VU573 analogs. Reported IC50 values were measured byTl+ ﬂux assay. Values are mean±SEM (n=3).
led to an analog compound with moderate selectivity for GIRK
(IC50 = 5.27μM) and weak inhibition of Kir2.3 and Kir7.1, with
IC50 values of 11.3 and 19.7μM, respectively. All other analogs
in which substitutions were made at both R and R′ groups led
to similar potency among the Kir2.3, Kir7.1, and GIRK chan-
nels as compared to VU573, but with weak inhibition for Kir1.1.
The development of two VU573 analogs, R70 and R5C (Table 1),
that retain activity toward GIRK and Kir2.3 but have lost activity
toward Kir7.1 suggest that chemically optimized analogs based on
the VU573 scaffold can be developed to increase their selectivity.
To determine if the apparent loss of activity is an artifact of
the Tl+ ﬂux assay or the use of the M125R mutant, we exam-
ined the effects of the VU573 analog R70 on wild type Kir7.1
currents in whole-cell patch clamp experiments. The cells were
voltage-clamped between −120 and 120mV in 20mV increments
from a −75-mV holding potential (Figure 6E). As illustrated in
the average current traces recorded before (Figure 6A) or during
bath application of 10μM R70 (Figure 6B), the analog had no
effect on wild typeKir7.1 activity. In contrast, subsequent addition
of 10μM VU573 led to a near complete inhibition of the chan-
nel (Figures 6C). The mean± SEM current–voltage relationships
recorded in the three conditions are shown in Figure 6D.
DISCUSSION
The Tl+ ﬂux assay developed by Weaver et al. (2004) and subse-
quently commercialized by Invitrogen under the FluxOR© label
has had a major impact on high-throughput screening for potas-
sium channels. The assay takes advantage of the fact that Tl+
readily permeates most K+ channel pores. With the exception of
wild type Kir7.1, the assay seems to be particularly well suited for
inward rectiﬁer K+ channels due to their high open probability
near the resting membrane potential of a cell. This obviates the
need for depolarizing the cell with a high-potassium step to open
voltage-gated K+ channels. To date, Tl+ ﬂux assays have been
reported for the inward rectiﬁers Kir1.1 (Lewis et al., 2009), Kir2.1
(Wang et al., 2010), Kir2.3 (this study), Kir3.1/3.2 (Niswender
et al., 2008), and Kir7.1-M125R (this study). Tl+ ﬂux assays have
also been developed for some ligand- and voltage-gated potassium
channels, including SK3 andKCNQ2 (Weaver et al., 2004),KCNQ4
(Li et al., 2011), and hERG (Titus et al., 2009; Bridal et al., 2010;
Huang et al., 2010; Schmalhofer et al., 2010; Zou et al., 2010). A
Tl+ ﬂux assay was used to screen formodulators of the potassium-
chloride co-transporter KCC2 (Delpire et al., 2009). This is notable
FIGURE 6 | Lack of effect of R70 on wild type Kir7.1 activity. Average
Kir7.1 current traces (n=4 each) recorded in the absence (A) or presence of
(B) 10μM R70 or (C) 10μMVU573. (D) Mean±SEM (n=4)
current–voltage Kir7.1 relationships recorded in the indicated conditions
using the voltage-clamp protocol shown in (E).
because KCC2 is electroneutral and therefore cannot be screened
using voltage-sensitive dyes. Thus, the Tl+ ﬂux assay appears to
be broadly adaptable to both electrogenic and electroneutral K+
transport proteins.
In the present study, Tl+ ﬂux- and electrophysiological-based
counterscreens revealed a preferential inhibitor of GIRK, Kir2.3,
and Kir7.1. It is unclear why IC50 values are lower in oocytes
compared to mammalian cells, but likely reﬂects differences in
membrane properties or intracellular factors between the two
cell types. VU573 inhibits GIRK independent of GPCR stimu-
lation and does not discriminate between cardiac (Kir3.1/3.4) and
neuronal (Kir3.1/3.2) forms of the channel. The latter observa-
tion suggests that the VU573 binding site is located within the
Kir3.1 subunit, which is common to both heteromeric forms, or
is shared between all three subunits. Pharmacology experiments
on homotetrameric Kir3.1, Kir3.2, and Kir3.4 channels should
help resolve the issue. Given the broad tissue distribution and
important physiological functions of GIRK channels in multiple
organ systems, the development of subtype selective modulators
may be important for developing, for example, cardiac-speciﬁc
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drugs to treat atrial ﬁbrillation without toxic side effects on the
nervous system. The availability of high-resolution crystal struc-
tures of the GIRK cytoplasmic domain (Nishida and Mackinnon,
2002), GIRK-bacterial Kir channel chimeras (Nishida et al., 2007)
and now full-length mammalian Kir2.2 (Tao et al., 2009) should
be helpful in guiding and interpreting experiments to deﬁne the
molecular binding site for VU573 and other GIRK antagonists.
The relatively ﬂat SAR of VU573 against GIRK, Kir2.3, and Kir7.1
suggests that the VU573 scaffold may be amenable to the addi-
tion of diazirine or other light-reactive moieties for photoafﬁnity
labeling of the channels for identiﬁcation of the binding site using
mass spectrometry. A detailed understanding of both unique and
overlapping binding sites will provide novel insights into the mol-
ecular architecture of GIRK and should facilitate the development
of subtype-speciﬁc inhibitors.
Members of the Kir2.X subfamily, including Kir2.1, Kir2.2,
Kir2.3, Kir2.4, and Kir2.6, are broadly expressed in neurons,
cardiac, skeletal and smooth muscle cells, endothelial cells,
macrophages, and epithelial cells (De Boer et al., 2010a). Much
of our understanding of the physiology of Kir2.X channels comes
from studies of disease-causing mutations in humans (Plaster
et al., 2001; Ryan et al., 2010) and knockout mice (Zaritsky et al.,
2001). While it is clear from this work that Kir2.X channels
are essential in many organ systems, pinpointing their individ-
ual roles has been difﬁcult due to their overlapping expression
proﬁles, propensity to form Kir2.X heterotetramers and poorly
developed pharmacology. The development of subtype selective
Kir2.X inhibitors would undoubtedly bolster efforts to understand
the physiology and druggability of Kir2.X homo- and heteromeric
channels. To date, however, the inhibitor pharmacology of Kir2.X
channels is limited to barium, cesium, and a handful of non-
speciﬁc drugs such as chloroquine (Rodriguez-Menchaca et al.,
2008), meﬂoquine (Lopez-Izquierdo et al., 2011b), quinacrine
(Lopez-Izquierdo et al., 2011a), carvedilol (Ferrer et al., 2011),
tamoxifen (Ponce-Balbuena et al., 2009), and pentamidine (De
Boer et al., 2010b). Pregnenolone sulfate (Kobayashi et al., 2009)
and ﬂecainide (Caballero et al., 2010) are activators of Kir2.3
and Kir2.1, respectively. Like VU573 (this study), meﬂoquine,
quinacrine, tamoxifen, and carvedilol preferentially inhibit Kir2.3
over Kir2.1. Electrophysiological analysis of mutagenized chan-
nels suggests that chloroquine and pentamidine are cytoplasmic
pore blockers, whereas meﬂoquine and carvedilol appear to dis-
rupt channel interactions with the activating membrane phos-
pholipid phosphatidylinositol 4,5-bisphosphate (PIP2). There is
evidence that quinacrine has a complex mechanism of action
involving both pore block and disruption of channel-PIP2 inter-
actions. Because VU573 is also a preferential inhibitor of Kir2.3,
we are currently testing if it shares a common mechanism of
action and binding site(s) with these drugs. Looking ahead, it
will be important to determine whether VU573 or any of the
aforementioned drugs show preference for homomeric versus
heteromeric Kir2.X channels. These studiesmay help informmed-
icinal chemistry efforts to develop subtype-speciﬁc inhibitors of
Kir2.X channels.
To our knowledge, VU573 is only the second and most potent
Kir7.1 inhibitor available. We recently reported that the∼300 nM
Kir1.1 inhibitor 7,13-bis[(4-nitrophenyl)methyl]-1,4,10-trioxa-
7,13-diazacyclopentadecanedihydrochloride, or VU590, inhibits
Kir7.1 with an IC50 of approximately 8μM, making VU590 the
ﬁrst publically disclosed small-molecule inhibitor of both Kir1.1
and Kir7.1 (Lewis et al., 2009). In the present study, we found that
VU573 preferentially inhibits Kir7.1 (IC50∼ 1μM) over Kir1.1
(IC50∼ 19μM).
Kir7.1 is widely expressed in the brain, retinal pigment epithe-
lial cells of the eye, the choroid plexus, and epithelial cells of the
intestine, nephron, and inner ear (Krapivinsky et al., 1998; Naka-
mura et al., 1999; Ookata et al., 2000; Pondugula et al., 2006; Yang
et al., 2008). Very little is known about the physiology of Kir7.1
due in part to the unusually small (i.e., ∼50 fS) unitary conduc-
tance of the channel. This precludes the use of single-channel
recording techniques to study its activity in native cell types,where
other inward rectiﬁers of larger unitary conductances are often co-
expressed. Whole-cell patch clamp recordings could conceivably
be used to dissect out the relative contributions of Kir7.1 and
other Kir channels to the macroscopic current provided that spe-
ciﬁc blockers were available. This scenario highlights the need for
better pharmacological modulators of Kir7.1 and other members
of the Kir channel family. The discovery of VU573 and its inactive
analogs represent important steps toward ﬁlling this gap. Further-
more, and importantly, the development of a robust Tl+ ﬂux assay
using the Kir7.1-M125R mutant will enable HTS for chemically
diverse modulators of the channel.
Interestingly, heritable mutations in the Kir7.1-encoding gene
KCNJ13 were recently found in patients with two forms of retinal
disease (Hejtmancik et al., 2008; Sergouniotis et al., 2011). These
ﬁndings conﬁrm the importance of Kir7.1 in retinal pigmented
epithelia of the eye and raise questions regarding the detailed phys-
iological roles of Kir7.1 in the eye and other organ systems. The
development of potent and selective Kir7.1 antagonists will greatly
facilitate those efforts.
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